High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.

BACKGROUND Rifampin is used as adjunctive therapy for Clostridium difficile-associated disease, and the drug's derivative, rifaximin, has emerged as an attractive antimicrobial for treatment of C. difficile-associated disease. Rifampin resistance in C. difficile strains has been reported to be uncommon. METHODS We examined the prevalence of rifampin resistance among 470 C. difficile isolates (51.1% during 2001-2002 and 48.9% during 2005) from a large teaching hospital. Rifampin sensitivity was performed using E-test. The epidemic BI/NAP1 C. difficile clone was identified by tcdC genotyping and multilocus variable number of tandem repeats analysis. A 200-base pair fragment of the rpoB gene was sequenced for 102 isolates. Data on rifamycin exposures were obtained for all patients. RESULTS Rifampin resistance was observed in 173 (36.8%) of 470 recovered isolates and 167 (81.5%) of 205 of epidemic clone isolates (P < .001). Six rpoB genotypes were associated with rifampin resistance. Of 8 patients exposed to rifamycins, 7 had rifampin-resistant C. difficile, compared with 166 of 462 unexposed patients (relative risk, 2.4; 95% confidence interval, 1.8-3.3). CONCLUSIONS Rifampin resistance is common among epidemic clone C. difficile isolates at our institution. Exposure to rifamycins before the development of C. difficile-associated disease was a risk factor for rifampin-resistant C. difficile infection. The use of rifaximin may be limited for treatment of C. difficile-associated disease at our institution.

[1]  D. Gerding,et al.  Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile , 2008, Antimicrobial Agents and Chemotherapy.

[2]  C. Woods,et al.  Comparison of Seven Techniques for Typing International Epidemic Strains of Clostridium difficile: Restriction Endonuclease Analysis, Pulsed-Field Gel Electrophoresis, PCR-Ribotyping, Multilocus Sequence Typing, Multilocus Variable-Number Tandem-Repeat Analysis, Amplified Fragment Length Polymorphis , 2007, Journal of Clinical Microbiology.

[3]  Jane W. Marsh,et al.  Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  D. Gerding,et al.  In Vitro Activities of 15 Antimicrobial Agents against 110 Toxigenic Clostridium difficile Clinical Isolates Collected from 1983 to 2004 , 2007, Antimicrobial Agents and Chemotherapy.

[5]  D. Gerding,et al.  Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Stockman.  A Predominantly Clonal Multi-Institutional Outbreak of Clostridium difficile—Associated Diarrhea With High Morbidity and Mortality , 2007 .

[7]  Jane W. Marsh,et al.  tcdC Genotypes Associated with Severe TcdC Truncation in an Epidemic Clone and Other Strains of Clostridium difficile , 2006, Journal of Clinical Microbiology.

[8]  Jane W. Marsh,et al.  Multilocus Variable-Number Tandem-Repeat Analysis for Investigation of Clostridium difficile Transmission in Hospitals , 2006, Journal of Clinical Microbiology.

[9]  Julian Parkhill,et al.  The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome , 2006, Nature Genetics.

[10]  Stuart Johnson,et al.  An epidemic, toxin gene-variant strain of Clostridium difficile. , 2005, The New England journal of medicine.

[11]  Ken Dewar,et al.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. , 2005, The New England journal of medicine.

[12]  L. Valiquette,et al.  Mortality attributable to nosocomial Clostridium difficile–associated disease during an epidemic caused by a hypervirulent strain in Quebec , 2005, Canadian Medical Association Journal.

[13]  Carlene A. Muto,et al.  A Large Outbreak of Clostridium difficile–Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone Use , 2005, Infection Control &#x0026; Hospital Epidemiology.

[14]  W. Nicholson,et al.  Novel rpoB Mutations Conferring Rifampin Resistance on Bacillus subtilis: Global Effects on Growth, Competence, Sporulation, and Germination , 2004, Journal of bacteriology.

[15]  C. Sirio,et al.  Fulminant Clostridium difficile: An Underappreciated and Increasing Cause of Death and Complications , 2002, Annals of surgery.

[16]  E. Palazzini,et al.  In Vitro Activity and Fecal Concentration of Rifaximin after Oral Administration , 2000, Antimicrobial Agents and Chemotherapy.

[17]  A. Marchese,et al.  In vitro Activity of Rifaximin, Metronidazole and Vancomycin against Clostridium difficile and the Rate of Selection of Spontaneously Resistant Mutants against Representative Anaerobic and Aerobic Bacteria, Including Ammonia-Producing Species , 2000, Chemotherapy.